The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...

HealthDay News — Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.

After proper training on subcutaneous injection technique, the prefilled syringe may be administered by the patient or caregiver.

Uplizna gains new indication; Vanrafia approved for proteinuria in IgAN; Erzofri now available for schizophrenia; setmelanotide shows promise in hypothalamic obesity; GLP-1RAs may reduce dementia risk ...

HealthDay News — Among US adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022, according ...

Physicians should counsel patients considering whether to start treatment for chronic noncancer pain about benefits and harms of cannabis or cannabinoids.

The Dexcom G7 15 Day CGM system is a wearable sensor that continuously measures glucose levels and transmits readings every 5 minutes with no fingersticks or scanning required.

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics Application (sBLA) for fremanezumab-vfrm to include the ...

Seventy-four percent of respondents unaware of FDA-approved treatments; 56% said these options had not been discussed by clinician.

Relevant risk for interaction seen with cardiac implantable electronic devices; no signs of cardiac damage seen during testing.

Compounded versions, made during shortages, have cost less than $200, but regulators plan to stop allowing those soon.

A statistically significantly lower risk of dementia or cognitive impairment was observed with GLP-1RAs, though not with SGLT2is or pioglitazone.